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Introduction {#s1}
============

Breast cancer is one of the most common malignancies among women worldwide ^[@R1],[@R2]^. Currently, more women survive due to earlier diagnosis and better therapy ^[@R3],[@R4]^. However, the morbidity and mortality of breast cancer have increased in most developing countries^[@R5]^. It is well-established that family or personal history of cancer, nulliparous, and history of hormone replacement therapy and different genetic background are most known risk factors for breast cancer ^[@R6]^. Breast cancer is one of the first multifactorial conditions to be evaluated using molecular genetics techniques ^[@R6]-[@R8]^. It is estimated that 15- 30% of hereditary breast cancer cases are due to known highly penetrant genes such as BRCA1 and BRCA2 9. More than 1,000 different breast cancer-associated mutations in each gene have been documented. However, a few of these mutations could be clearly identified as pathological ^[@R9]-[@R11]^.

Genetic variations in *SULT1A1* gene are increasingly studied for an increased different cancer risk because of the critical roles in catalyzing the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds ^[@R12]^. In particular, *SULT1A1* has high activity towards a wide range of substrates including environmental carcinogens such as tobacco. The *SULT1A1* gene is located on chromosome 16p12.1-p11.2, spans approximately 5.1 kb and contains nine exons that range in length from 74 to 347 bp ^[@R13]^. To date, the Arg213His (rs9282861) polymorphism is most widely studied SNP within *SULT1A1* gene. The Arg213His polymorphism is located in exon 7 with G to A transition, at nucleotide 638 (codon 213) leading to an arginine (Arg) to histidine (His) amino acid substitution ^[@R14]^. Functional studies have reported that the variant A allele (His allele) is associated with lower sulfotransferase activity and thermal stability compared with the wild-type G allele (Arg allele) ^[@R15],[@R16]^.

So far, there were so many reports about the association of *SULT1A1* Arg213His (rs9282861) polymorphism with breast cancer risk ^[@R17]-[@R35]^. On the whole, these studies results were conflicting and inconclusive, probably due to the relatively small size, ethnic background, uncorrected multiple hypothesis testing, and publication bias. It is known that meta-analysis is a statistical procedure for combining data from multiple studies to produce a single estimate on the same outcome of interest with enhanced evaluation. Therefore, current systematic review and meta-analysis was performed from all eligible studies to derive a more precise estimation the association between *SULT1A1* Arg213His (rs9282861) polymorphism and breast cancer risk.

Methods {#s2}
=======

Search Strategy {#s2-0-1}
---------------

We performed a systematic literature search of electronic databases such as PubMed, Embase, ISI Wed of Knowledge, Google scholar, Scopus, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI) and Chinese Wan Fang databases to identify studies that evaluated the association between *SULT1A1 Arg213His* (rs9282861) polymorphism and the risk of breast cancer up to October 5, 2017. The search strategy identified all possible studies using combinations of the following keywords: Sulfotransferase Family 1A Member, *SULT1A1* gene, G638A, Arg213His, rs9282861, and polymorphism, genetic polymorphism, single nucleotide polymorphism, SNP mutation, and breast, breast cancer, breast malignancy, breast tumor, breast carcinoma, and breast neoplasm. In addition, manual searching was carried out to ensure that no relevant studies were missed in the database search by scanning the review articles, clinical trials, and meta-analyses. No language restrictions were imposed.

Inclusion and Exclusion Criteria {#s2-0-2}
--------------------------------

To be eligible for the inclusion criteria in the meta-analysis, the following criteria were used: a) case-control or cohort design; b) evaluating the associations between *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer risk; c) providing sufficient data to estimate the odds ratio (OR) with the corresponding 95% confidence interval (95%CI). Studies were excluded if the following criteria were satisfied: a) Abstracts, case reports, case-only articles, family-based studies, reviews articles and repeated literatures; b) duplicate of previous publications; c) not provided sufficient data (e.g. neither the frequency nor the number of genotype was given) for calculation.

Data Extraction {#s2-0-3}
---------------

All data were extracted independently by two authors using a standardized data extraction form and according to the inclusion criteria listed above. The following elements were extracted for each included study: first author name, year of publication, country, ethnicity, source of control groups, genotyping method, total number of cases and controls, minor allele frequency (MAF) in control subjects, *P* value of the Hardy--Weinberg equilibrium (HWE) test in the control. Different ethnic descents were classified as Caucasian, Asian, Latinos or Mixed (derived from an admixture of different ethnic groups). Disagreements between the two investigators were resolved by discussing with a third investigator. If more than one article were published using the same data, only the newest study and with largest sample size was selected. Moreover, the quality of selected studies was tested by the confirmation of HWE in control groups, and studies without the confirmation of HWE in controls were defined as low-quality studies, while studies with the confirmation of HWE in controls were defined as high-quality studies.

Statistical Analysis {#s2-0-4}
--------------------

Crude odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to assess the strength of association between the *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer risk. The pooled ORs were determined for *SULT1A1 Arg213His* (rs9282861) polymorphism under the allele model (A vs. G), the homozygote model (AA vs. GG), the heterozygote model (AG vs. GG), the dominant model (AA+AG vs. GG), and the recessive model (AA vs. AG+GG). The significance of the pooled OR was determined by the Z-test, in which *P*\<0.05 was considered as statistically significant. The Chi-square-based Q-test and I2-statistics were employed for evaluating the between-study heterogeneity36,37. A *P*-value greater than 0.10 for the Q-test or I2 less than 50% indicates a lack of heterogeneity among studies, so the pooled OR estimate of the included studies was obtained by the fixed-effects model (Mantel-Haenszel method) 38. Otherwise, the random-effects model (DerSimonian-Laird method) was used 39. Hardy-Weinberg equilibrium (HWE) in the control group was calculated by the Chi-square test for goodness of fit, If *P* value \> 0.05, the genotype distribution of control population conformed to HWE. Furthermore, to explore the sources of heterogeneity, subgroup analysis we conducted based on ethnicity, source of controls and studies quality. To validate the reliability of the results, sensitivity analysis was performed though omitting one case-control study each time, as well as limiting this meta-analysis to studies which were conformed to HWE. Publication bias was evaluated by Begg's test and Egger's test (*P* \<0.05 was considered statistically significant)40,41. If publication bias existed, the Duval and Tweedie non-parametric ''trim and fill'' method was used to adjust for it. All statistical analyses including meta-regression, sensitivity analysis, subgroup analysis, and publication bias assessment were performed using Comprehensive Meta-Analysis (CMA) software version 2.0 (Biostat, USA). Two-sided *P* values \< 0.05 were considered statistically significant.

Results {#s3}
=======

Characteristics of Studies {#s3-0-1}
--------------------------

As shown in [Figure 1](#F1){ref-type="fig"}, we initially identified 187 potentially relevant studies from database searching and 3 studies from manual retrieval. After screening of titles or abstracts duplicates were excluded resulting in 112 publications. An additional 92 publications were excluded because the studies were reviews, case reports, letter to editor, not reporting the usable data, other polymorphisms of *SULT1A1* gene, not related to breast cancer or reported other diseases. Finally, a total of 20 studies with 11,077 cancer cases and 14,798 controls met the inclusion criteria. Study characteristics are summarized in [Table 1](#T1){ref-type="table"}. The included studies were published from 2000 to 2013. Of those studies, there were twelve studies of Caucasian descendants and eight studies of Asian descendants. The countries of these studies were USA, Austria, India, Korea, Sweden, Germany, Finland, China, Taiwan, Russia, and Italy. All the 20 eligible studies were case-control studies, 11 of them were in a population-based design and 8 studies were hospital based. The genotyping for *SULT1A1 Arg213His* (rs9282861) polymorphism was performed by five genotyping methods including real-time PCR (RT-PCR), PCR-restriction fragment length polymorphism (PCR-RFLP), TaqMan, Genotyping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and direct Sequencing. The distribution of genotype in the controls of the studies was not in agreement with Hardy-Weinberg equilibrium in six studies, which were further tested in the sensitivity analyses and subgroup analysis of studies with high quality. The detailed characteristics of each study and *SULT1A1 Arg213His* (rs9282861) polymorphism genotype distributions included in the meta-analysis are presented in [Table 1](#T1){ref-type="table"}.
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###### Main characteristics of studies included in this meta-analysis

  ----------------------- ----------------------- -------------- ----------------- ---------- ------------- ----------- -------------- ---------- --------- ------ ------ ------ ----- ------ ------ ------- -------
  **First author/Year**   **Country ethnicity**   **SOP**        **Genotyping**\   **Case**   **Control**   **Cases**   **Controls**   **MAFs**   **HWE**                                                    
                                                                 **method**                                                                                                                                  

  **Genotype**            **Allele**              **Genotype**   **Allele**                                                                                                                                  

  **GG**                  **AG**                  **AA**         **G**             **A**      **GG**        **AG**      **AA**         **G**      **A**                                                      

  Seth 2000 17            USA(Caucasian)          HB             RT-PCR            444        227           229         176            39         634       254    110    94     23    314    140    0.308   0.193

  Zheng 2001 18           USA(Caucasian)          PB             PCR-RFLP          155        326           55          71             29         181       129    147    135    44    429    223    0.342   0.148

  Tang 2003 19            USA(Caucasian)          HB             PCR-RFLP          103        133           50          42             11         142       64     79     47     7     205    61     0.229   0.997

  Langsenlehner 2004 20   Austria (Caucasian)     PB             TaqMan            498        499           201         250            47         652       344    224    212    63    660    338    0.338   0.249

  Chacko 2004 21          India(Asian)            HB             PCR-RFLP          140        140           76          56             8          208       72     95     41     4     231    49     0.175   0.866

  Choi 2005 22            Korea(Asian)            Mixed          TaqMan            986        1045          796         190            0          1782      190    830    215    0     1875   215    0.102   0.001

  Jerevall 2005 23        Sweden(Caucasian)       PB             PCR-RFLP          229        228           80          121            28         280       178    84     106    38    274    182    0.399   0.642

  Le Marchand 2005 24     USA(Caucasian)          PB             PCR-RFLP          1339       1370          801         424            114        2026      652    782    484    104   2048   692    0.252   0.017

  Lilla 2005 25           Germany(Caucasian)      PB             PCR-RFLP          419        884           198         169            52         565       273    374    403    107   1151   617    0.349   0.922

  Sillanpaa 2005 26       Finland(Caucasian)      PB             PCR-RFLP          480        478           145         229            106        519       441    147    221    110   515    441    0.461   0.127

  Yang 2005 27            China(Asian)            PB             MALDI-TOF         1102       1147          921         181            0          2023      181    977    170    0     2124   170    0.074   0.006

  Cheng 2005 28           Taiwan(Asian)           HB             PCR-RFLP          468        740           439         27             2          905       31     693    47     0     1433   47     0.031   0.372

  Han 2005 29             China(Asian)            HB             PCR-RFLP          209        426           160         41             8          364       54     355    61     10    771    81     0.095   0.001

  Gulyaeva 2008 30        Russia(Caucasian)       PB             PCR-RFLP          82         180           23          40             19         99        65     63     61     56    187    173    0.480   0.001

  Syamala 2010 31         India(Asian)            HB             PCR-RFLP          359        367           244         87             18         591       127    271    90     6     632    102    0.139   0.635

  Merie-Genica 2010 32    Germany(Caucasian)      PB             MALDI-TOF         3139       5426          1381        1332           426        4094      2184   2338   2430   658   7106   3746   0.345   0.491

  Serrano 2011 33         Italy(Caucasian)        HB             RT-PCR            46         136           24          18             4          66        26     71     55     10    197    75     0.275   0.883

  Khvostova 2012 34       Russia(Caucasian)       PB             PCR-RFLP          335        530           47          164            103        275       395    166    261    103   593    467    0.440   0.982

  Lee 2012 35             China (Asian)           PB             Sequencing        400        400           300         83             17         683       117    310    78     12    698    102    0.127   0.013

  Kumar 2013 42           India(Asian)            HB             PCR-RFLP          144        116           117         25             2          259       29     111    5      0     227    5      0.021   0.812
  ----------------------- ----------------------- -------------- ----------------- ---------- ------------- ----------- -------------- ---------- --------- ------ ------ ------ ----- ------ ------ ------- -------

SOP, source of population; HB, Hospital-based study; PB, Population-based study; RT-PCR, Real-Time PCR; PCR-RFLP, PCR-restriction fragment length polymorphism; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS); MAFs, Minor Allele Frequencies; HWE, Hardy--Weinberg equilibrium.

Quantitative Synthesis {#s3-0-2}
----------------------

[Table 2](#T2){ref-type="table"} listed the main results of the meta-analysis of *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer risk. The random effects model was chosen to synthesize the data from the allelic model, homozygote, heterozygote, dominant model and recessive model. Overall, there was a significant association between *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer in the allele mode (A vs. G: OR=1.117, 95% CI: 1.011, 1.233, *P*=0.029) and the homozygote model (AA vs. GG: OR=1.288, 95% CI: 1.036, 1.601, *P*= 0.022), but not in the heterozygote model (AG vs. GG: OR = 0.854, 95% CI 0.705-1.036, *P*= 0.109), the dominant model (AA+AG vs. GG: OR=1.109, 95% CI: 0.990, 1.241, *P*= 0.073), and the recessive model (AA vs. AG+GG: OR=1.144, 95% CI: 0.969, 1.351, *P*= 0.112).

In the subgroup analysis by the ethnicity, a significant association between the *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer was observed in Asians in the allele model (A vs. G: OR=1.117, 95% CI: 1.011, 1.233, *P*= 0.020), the homozygote model (AA vs. GG: OR=2.112, 95% CI: 1.342, 3.323, *P*= 0.001), the heterozygote model (AG vs. GG: OR=0.468, 95% CI: 0.249, 0.881, P=0.019), the dominant model (AA+AG vs. GG: OR=1.237, 95% CI: 1.008, 1.518, *P*=0.041) and the recessive model (AA vs. AG+GG: OR=1.990, 95% CI: 1.268, 3.125, *P*=0.003), but not in the Caucasian populations.

Moreover, the studies were stratified on the basis of genotyping method, source of control subjects and high quality studies (HWE status). In the PCR-RFLP group, significantly increased association between *SULT1A1 Arg213His* polymorphism and risk of breast cancer were found in the allele mode (A vs. G: OR=1.209, 95% CI: 1.019, 1.435, *P*=0.030), the homozygote model (AA vs. GG: OR=1.504, 95% CI: 1.081, 2.093, *P*=0.015), and in the heterozygote model (AG vs. GG: OR=0.753, 95% CI: 0.570, 0.993, *P*=0.045). Interestingly, the stratifying by source of population showed that *SULT1A1 Arg213His* (rs9282861) polymorphism was significantly associated with breast cancer risk in the allele mode (A vs. G: OR=1.319, 95% CI: 1.044, 1.666, *P*=0.020) and the homozygote model (AA vs. GG: OR=1.523, 95% CI: 1.067, 2.175, *P*=0.021), the dominant model (AA+AG vs. GG: OR=1.319, 95% CI: 1.013, 1.717, *P*=0.040), and the recessive model (AA vs. AG+GG: OR=1.459, 95% CI:1.030, 2.066, *P*=0.033) in the hospital based group, but not population based ([Table 2](#T2){ref-type="table"}). Subgroup analysis of studies with high quality showed that there was a significant association between *SULT1A1 Arg213His* (rs9282861) polymorphism and increased risk of breast cancer in the allele model (OR=1.174, 95% CI: 1.026, 1.343, *P*=0.019), the homozygote model (OR=1.343, 95% CI: 1.015, 1.777, *P*=0.039) and the dominant model (AA+AG vs. GG: OR=1.175, 95% CI: 1.005, 1.373, *P*=0.043, [Table 2](#T2){ref-type="table"}).

###### The meta-analysis of *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer risk

  --------------------------------- --------------- ------------------- ------------------- ------------------- ---------------- ---------------------- -------------- -------- ------- ------- -------
  **Subgroup**                      **Study No.**   **Genetic Model**   **Type of Model**   **Heterogeneity**   **Odds Ratio**   **Publication Bias**                                           
  **I2 (%)**                        **PH**          **OR**              **95% CI**          **Ztest**           **POR**          **PBeggs**             **PEggers**                             
  **Overall**                       20              A vs. G             Random              73.77               0.001            1.117                  1.011, 1.233   2.184    0.029   0.029   0.077
                                    18              AA vs. GG           Random              65.91               0.001            1.288                  1.036, 1.601   2.283    0.022   0.111   0.129
                                    18              AG vs. GG           Random              53.88               0.004            0.854                  0.705, 1.036   -1.604   0.109   0.225   0.178
                                    18              AA+AG vs. GG        Random              66.10               0.001            1.109                  0.990, 1.241   1.792    0.073   0.047   0.007
                                    18              AA vs. AG+GG        Random              50.44               0.008            1.144                  0.969, 1.351   1.589    0.112   0.100   0.284
  **By Ethnicity**                                                                                                                                                                              
  **Caucasian**                     12              A vs. G             Random              77.83               0.001            1.061                  0.942, 1.194   0.971    0.331   0.303   0.589
                                    12              AA vs. GG           Random              72.47               0.001            1.167                  0.925, 1.473   1.302    0.193   0.945   0.665
                                    12              AG vs. GG           Random              58.37               0.006            0.915                  0.755, 1.108   -0.913   0.361   0.945   0.833
                                    12              AA+AG vs. GG        Random              65.76               0.001            1.045                  0.914, 1.196   0.648    0.517   0.195   0.372
                                    12              AA vs. AG+GG        Random              56.35               0.009            1.067                  0.900, 1.264   0.745    0.456   0.731   0.619
  **Asian**                         8               A vs. G             Random              62.04               0.010            1.251                  1.037, 1.509   2.335    0.020   0.063   0.011
                                    6               AA vs. GG           Fixed               0.00                0.732            2.112                  1.342, 3.323   3.231    0.001   0.452   0.144
                                    6               AG vs. GG           Fixed               16.69               0.306            0.468                  0.249, 0.881   -2.353   0.019   0.707   0.253
                                    6               AA+AG vs. GG        Random              61.49               0.011            1.237                  1.008, 1.518   2.039    0.041   0.035   0.012
                                    6               AA vs. AG+GG        Fixed               0.00                0.724            1.990                  1.268, 3.125   2.990    0.003   0.452   0.146
  **By Genotyping Method**                                                                                                                                                                      
  **PCR-RFLP**                      13              A vs. G             Random              81.51               0.001            1.209                  1.019, 1.435   2.174    0.030   0.058   0.108
                                    13              AA vs. GG           Random              71.98               0.001            1.504                  1.081, 2.093   2.423    0.015   0.360   0.148
                                    13              AG vs. GG           Random              56.23               0.007            0.753                  0.570, 0.993   -2.007   0.045   0.246   0.045
                                    13              AA+AG vs. GG        Random              73.95               0.001            1.207                  0.995, 1.464   1.912    0.056   0.127   0.026
                                    13              AA vs. AG+GG        Random              56.18               0.007            1.249                  0.983, 1.586   1.822    0.068   0.360   0.208
  **Source of Population**                                                                                                                                                                      
  **Hospital Based**                8               A vs. G             Random              63.32               0.008            1.319                  1.044, 1.666   2.322    0.020   0.265   0.062
                                    8               AA vs. GG           Fixed               33.80               0.158            1.523                  1.067, 2.175   2.316    0.021   1.000   0.058
                                    8               AG vs. GG           Fixed               31.81               0.174            0.694                  0.470, 1.024   -1.842   0.066   0.901   0.069
                                    8               AA+AG vs. GG        Random              60.17               0.014            1.319                  1.013, 1.717   2.058    0.040   0.173   0.074
                                    8               AA vs. AG+GG        Fixed               23.15               0.245            1.459                  1.030, 2.066   2.128    0.033   0.536   0.044
  **Population Based**              11              A vs. G             Random              78.40               0.001            1.070                  0.953, 1.201   1.144    0.253   0.350   0.543
                                    10              AA vs. GG           Random              75.54               0.001            1.181                  0.925, 1.509   1.337    0.181   0.858   0.671
                                    11              AG vs. GG           Random              64.39               0.003            0.909                  0.740, 1.117   -0.906   0.365   1.000   0.832
                                    11              AA+AG vs. GG        Random              67.87               0.001            1.058                  0.929, 1.203   0.850    0.395   0.350   0.165
                                    10              AA vs. AG+GG        Random              60.88               0.006            1.073                  0.898, 1.281   0.778    0.437   0.591   0.547
  **High Quality Studies ( HWE)**                                                                                                                                                               
                                    14              A vs. G             Random              78.55               0.001            1.174                  1.026, 1.343   2.340    0.019   0.021   0.083
                                    14              AA vs. GG           Random              72.94               0.001            1.343                  1.015, 1.777   2.064    0.039   0.511   0.187
                                    14              AG vs. GG           Random              46.92               0.027            0.904                  0.746, 1.095   -1.034   0.301   0.912   0.754
                                    14              AA+AG vs. GG        Random              70.51               0.001            1.175                  1.005, 1.373   2.026    0.043   0.062   0.009
                                    14              AA vs. AG+GG        Random              57.15               0.004            1.168                  0.953, 1.432   1.496    0.135   0.381   0.346
  --------------------------------- --------------- ------------------- ------------------- ------------------- ---------------- ---------------------- -------------- -------- ------- ------- -------

PCR-RFLP, PCR-restriction fragment length polymorphism; HWE, Hardy--Weinberg equilibrium.

Minor allele frequencies (MAFs) {#s3-0-6}
-------------------------------

The MAFs for the *SULT1A1 Arg213His* (rs9282861) polymorphism in the healthy controls is presented in [Table 1](#T1){ref-type="table"}. The allele and genotype distributions of *SULT1A1 Arg213His* (rs9282861) polymorphism exhibited ethnic variations. The allele and genotype distributions of 213His allele in the Caucasian and Asians populations were 32.75% (17.5%-48.0%) and 7.4% (2.1%-12.7%), respectively. Thus, the frequency of the 213His allele in Asians was less than Caucasians.

Heterogeneity analysis {#s3-0-3}
----------------------

There was a significant heterogeneity in overall comparisons under all genetic models among the overall 20 studies of the *SULT1A1 Arg213His* (rs9282861) polymorphism (e.g., allele model: Q= 72.44 on 19 d.f (Q), *P*= ≤0.001, I2 = 73.77%; and dominant model: Q= 189.01 on 17 d.f (Q), *P*= ≤0.001, I2 = 91%). Therefore, we have performed subgroup analyses by ethnicity and HWE status to explore the source of heterogeneity. The I2 decreased obviously and *P* value exceeded 0.05 under the homozygote, heterozygote and recessive models among Asians, while it was still significant under all genetic models among Caucasians ([Table 2](#T2){ref-type="table"}). The results indicated that ethnicity may be a source of heterogeneity in the current meta-analysis.

Test of heterogeneity and sensitivity analyses {#s3-0-4}
----------------------------------------------

There was significant heterogeneity among these studies for *SULT1A1 Arg213His* (rs9282861) polymorphism in the allele mode (A vs. G: *P*\<0.001), the homozygote model (AA vs. GG: *P*\<0.001), the heterozygote model (AG vs. GG: *P*=0.004), the dominant model (AA+AG vs. GG: *P*\<0.001), and the recessive model (AA vs. AG+GG: *P*=0.008). Then, the source of heterogeneity was assessed by meta-regression analysis. However, the ethnicity, genotyping methods, studies quality and source of population did not contribute to substantial heterogeneity in this meta-analysis ([Table 2](#T2){ref-type="table"}). In addition, the sensitivity analysis was performed to assess the reliability and conclusiveness of the overall results by repeating the meta-analysis sequentially removing each individual study. However, the results showed that the pooled ORs were not considerably affected by removing any individual study in all five genetic models, which indicated the reliability of our results.

Publication Bias {#s3-0-5}
----------------

We have used both Begg's funnel plot and Egger's test to access the small study effects of the literatures. The visual inspection of funnel plot revealed no obvious asymmetry in the allele ([Figure 2A](#F2){ref-type="fig"}), homozygote, heterozygote and recessive models. However, the results of Egger's test showed a publication bias for association of *SULT1A1 Arg213His* (rs9282861) polymorphism with risk of breast cancer in dominant model (AA+AG vs. GG: *P*~Begg~=0.047, *P*~Egger~=0.007, [Figure 2B](#F2){ref-type="fig"}). Therefore, the Duval and Tweedie non-parametric ''trim and fill'' method was used to adjust for publication bias. Meta-analysis with and without ''trim and fill'' did not draw different conclusion, indicating that the results were statistically robust ([Fig. 3B](#F3){ref-type="fig"}).
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Discussion {#s4}
==========

The pathogenesis of breast cancer is complex and genetic factor play an important role in breast cancer susceptibility. An increasing number of publications on genetic association studies, genome-wide association studies (GWASs), and relate meta-analyses have been published to clarify the association between different gene polymorphisms and breast cancer. To our knowledge, this is the most comprehensive and robust meta-analysis to explore and report the association between the *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer. The pooled ORs of 20 case-control studies with ^[@R11]^,077 cases and ^[@R14]^,798 controls in the current meta-analysis concluded that there was a significant correlation between *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer under allele mode (A vs. G: OR=1.117, 95% CI: 1.011-1.233, *P*=0.029) and homozygote model (AA vs. GG: OR=1.288, 95% CI: 1.036, 1.601, *P*=0.022).

Our results are inconsistent with the previous meta-analysis by Xiao et al., which not reported a significant association between *SULT1A1 Arg213His* polymorphism and breast cancer risk ^[@R12]^. The current meta-analysis is different from previous meta-analysis. We collected all 20 eligible studies, which include 13 studies used by Xiao et al., researches and seven new cases-control studies. It was remarkable that they have not included the Choi et al. 2003 22, Le Marchand et al. 2005 ^[@R24]^, Yang et al. 2005 ^[@R27]^, Han et al. 2006^[@R29]^, and Gulyaeva et al. 2008 ^[@R30]^ studies with that published up to their electronic researches due to lack of agreement with HWE. We analyzed the association between *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer in Caucasian and Asian populations. The association is significant in Asians under in the allele model (A vs. G: OR=1.117, 95% CI: 1.011, 1.233, *P*=0.020), the homozygote model (AA vs. GG: OR=2.112, 95% CI: 1.342, 3.323, *P*=0.001), the heterozygote model (AG vs. GG: OR=0.468, 95% CI: 0.249, 0.881, *P*=0.019), the dominant model (AA+AG vs. GG: OR=1.237, 95% CI: 1.008, 1.518, *P*=0.041) and the recessive model (AA vs. AG+GG: OR=1.990, 95% CI: 1.268, 3.125, *P*=0.003), but not among Caucasian populations. Our findings suggested that *SULT1A1 Arg213His* (rs9282861) polymorphism might have a susceptible nature in the Asians, but not in the Caucasians. Therefore, different populations lived in different environments and gene-environment interactions may partly affect the breast cancer susceptibility. Compared with the current meta-analysis, Xiao et al. not performed subgroup analysis by ethnicity for breast cancer ^[@R12]^. Therefore, Xiao et al., study essentially remains an open field as meta-analysis their results reliability due lack of subgroup analysis by ethnicity and the number of studies were considerably smaller than that needed to receive the robust conclusions.

Interestingly, stratified analysis according to genotyping method showed a significant association between *SULT1A1 Arg213His* polymorphism and increased risk of breast cancer in participants of those studies involving PCR-RFLP under the allele mode (A vs. G: OR=1.209, 95% CI: 1.019, 1.435, *P*=0.030), the homozygote model (AA vs. GG: OR=1.504, 95% CI:1.081, 2.093, *P*=0.015), and in the heterozygote model (AG vs. GG: OR=0.753, 95% CI: 0.570, 0.993, *P*=0.045). We suggested that this trend is possible for that most of the included studies mainly utilized PCR-RFLP method to genotyping. Moreover, this result should be carefully interpreted and confirmed by conducting further analysis of additional published studies.

Between-study heterogeneity might distort the conclusion of a meta-analysis ^[@R43],[@R44]^. The study designs, source of controls subjects, ethnicity, genotyping method, sample size, lifestyle, subject's age and gender may contribute to the heterogeneity ^[@R45]^. In the present meta-analysis, significant between-study heterogeneity was detected across studies under all models; therefore, we utilized the random-effects model to summarize the ORs. Additionally, in order to make the conclusion more credible, we performed the publication bias analysis and sensitivity analysis. Funnel plots suggested that no obvious publication bias was observed. Xiao et al. ^[@R12]^ removed the study conducted by Khvostova et al. ^[@R34]^ due to the low-quality and results indicated that this study influences the pooled estimates and the heterogeneity most in breast cancer subgroup. We have also removed Khvostova et al. ^[@R34]^ study, but there was no obvious effect on the pooled ORs and the corresponding CIs. In addition, we have performed the sensitivity analysis by removing those studies departed from HWE, but the results did not change meaningfully by excluding six studies departed from HWE or one study with low-quality. We suggest the relative small sample size status may be the reason for Xiao et al. ^[@R12]^ observations.

Despite the advantage of large sample size and no evidence of publication bias, the meta-analysis had several limitations that should be taken into account. First, the population data of *SULT1A1 Arg213His* (rs9282861) polymorphism are limited for the subgroup analysis, since there were not enough studies in other population or regions such as Africans and Middle East in this meta-analysis. Therefore there was insufficient statistical power to demonstrate the associations between the *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer risk in Africans or Middle East. Second, we only included articles that were published in English, and language bias might exist. Third, because of moderate to high heterogeneity in all five genetic models, we used the random effect model, which is not as reliable as the fixed-effects model and may potentially restrict the interpretation of the pooled risk estimates. Although the degree of heterogeneity was reduced (but not disappeared) by subgroup analyses based on ethnicity and HWE status, other sources of heterogeneity were not checked. Forth, in the current meta-analysis the design of all included studies was case control, therefore results more prone to selection bias. Fifth, the current meta-analysis results were based on unadjusted estimates, while a more precise analysis should be performed if all individual data available, which would allow for the adjustment by other co-variants including age, environmental exposures, smoking status, reproductive history, menopausal status and other lifestyle factors. Finally, gene-gene and gene-environment interactions which may modulate the breast cancer susceptibility were limited owing to the lack of the sufficient data in the eligible studies.

In summary, despite the limitations, this study is the most comprehensive, best available evidence and accurate meta-analysis focusing on the association between *SULT1A1 Arg213His* (rs9282861) polymorphism and risk of breast cancer. The present meta-analysis provided evidence of association between *SULT1A1 Arg213His* (rs9282861) polymorphism and increased breast cancer risk, especially among Asians. These results suggest that the *SULT1A1 Arg213His* (rs9282861) polymorphism is of high clinical relevance among Asians and would be a useful marker to identify women who are at higher risk for breast cancer. Moreover, well-designed epidemiological studies with larger sample size, carefully matching cases and control subjects and more ethnic groups are needed to validate these results. Further studies may focus on the influence of gene-gene and gene-environment interactions on the association of *SULT1A1 Arg213His* (rs9282861) polymorphism and breast cancer.
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-   The *SULT1A1 Arg213His* polymorphism is associated with increased risk of breast cancer.

-   The *SULT1A1 Arg213His* polymorphism may be associated with increased risk of breast cancer in **Asians**.

-   The *SULT1A1 Arg213His* polymorphism would be a useful marker to identify women who are at higher risk of breast cancer.
